Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-7 (rhBMP-7/rhOP-1): radiographic observations.
OBJECTIVE
The objective of this study was to radiographically evaluate the potential of a purpose-designed titanium porous-oxide implant surface coated with recombinant human bone morphogenetic protein-7 (rhBMP-7), also known as recombinant human osteogenic protein-1 (rhOP-1), to stimulate alveolar ridge augmentation.


METHODS
Six young-adult Hound Labrador mongrel dogs were used. Three 10 mm titanium oral implants per jaw quadrant were placed 5 mm into the alveolar ridge in the posterior mandible following surgical extraction of the pre-molar teeth and reduction of the alveolar ridge leaving 5 mm of the implants in a supra-alveolar position. The implants had been coated with rhBMP-7 at 1.5 or 3.0 mg/ml and were randomized to contralateral jaw quadrants using a split-mouth design. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants. Radiographic registrations were made immediately post-surgery (baseline), and at weeks 4 and 8 (end of study).


RESULTS
rhBMP-7-coated implants exhibited robust radiographic bone formation. At 8 weeks, bone formation averaged 4.4 and 4.2 mm for implants coated with rhBMP-7 at 1.5 and 3.0 mg/ml, respectively. There were no significant differences between the rhBMP-7 concentrations at any observation interval. A majority of the implant sites showed voids within the newly formed bone at week 4 that generally resolved by week 8. The newly formed bone assumed characteristics of the resident bone.


CONCLUSIONS
The titanium porous-oxide implant surface serves as an effective carrier for rhBMP-7 showing a clinically significant potential to stimulate local bone formation.
Leknes
Knut N
KN
Department of Clinical Dentistry-Periodontics, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway. knut.leknes@odont.uib.no
Yang
Jie
J
Qahash
Mohammed
M
Polimeni
Giuseppe
G
Susin
Cristiano
C
Wikesjö
Ulf M E
UM
D000539:Alveolar Process / Q000000981:diagnostic imaging / Q000601:surgery*; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D000818:Animals; D055419:Bone Morphogenetic Protein 7 / Q000502:physiology / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D003758:Dental Implantation, Endosseous / Q000379:methods; D015921:Dental Implants; D004285:Dogs; D006801:Humans; D008297:Male; D016348:Osseointegration / Q000502:physiology*; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D011859:Radiography; D011994:Recombinant Proteins; D014025:Titanium; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology
D055419:Bone Morphogenetic Protein 7; D020099:Coated Materials, Biocompatible; D015921:Dental Implants; D011994:Recombinant Proteins; D014025:Titanium